Figure 2From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesPharmacokinetics of dinaciclib following 2-hour infusion at different doses. Mean dinaciclib concentration-time profiles following 2-hour IV infusion on day 1 of cycle 1 (A), comparison of individual AUC(I) on days 1 and 15 of cycle 1 (B), and dinaciclib plasma concentrations at the end of each 2-hour infusion (C) (on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2) for subjects administered dinaciclib at 0.33Â mg/m2 to 14.0Â mg/m2. For AUC(l), lines connect day 1 and day 15 values for subjects with data on both days.Back to article page